Research Article

Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report

Bassem Refaat,1 Adel Galal El-Shemi,1,2 Ahmed Mohamed Ashshi,1 and Adnan AlZanbagi3

1 Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, P.O. Box 7607, Al Abdeyah, Makkah, Saudi Arabia
2 Department of Pharmacology, Faculty of Medicine, Assiut University, Assiut 6515, Egypt
3 Gastroenterology Department, King Abdullah Medical City, Makkah 21955, Saudi Arabia

Correspondence should be addressed to Bassem Refaat; bassem.refaat@yahoo.co.uk

Received 11 February 2014; Revised 21 February 2014; Accepted 7 March 2014; Published 1 April 2014

Aims. To measure the effect of pegylated interferon-α therapy on serum activin-A, activin-B, and follistatin and their correlation with viral load and liver fibrosis in chronic hepatitis C (CHC).

Methods. This study was cross-sectional and sera were collected from 165 participants classified into 7 groups: 40 healthy negative control, 33 treatment naïve patients as positive control, 19 patients at week 4, 22 at week 12, and 19 at week 24 of treatment initiation and 21 responders and 11 nonresponders at the end of 48-week treatment protocol. Serum candidate proteins were measured using ELISA and liver fibrosis was assessed by AST platelet ratio index (APRI).

Results. CHC significantly increased activins and decreased follistatin compared to negative control (P<0.05). Activin-A and follistatin levels returned to the level of negative control group at weeks 4, 12, and 24 following treatment initiation and were significantly different from positive control (P<0.05). Both proteins were significantly different between responders and nonresponders. Activin-A correlated positively and significantly with the viral load and APRI.

Conclusion. CHC modulates serum activin-A and follistatin and they appear to be influenced by pegylated interferon-α therapy. Further studies are needed to explore the role of activins in CHC.

1. Introduction

Infection with hepatitis C virus (HCV) is a global health problem and it infects at least 170 million people worldwide with an estimated prevalence of 3 to 4 million newly acquired infections per year [1]. Although future treatment for chronic hepatitis C (CHC) is interferon free and it achieves higher sustained viral response, HCV infection is still currently treated with a weekly injection of pegylated interferon-α-2a or -2b plus a daily weight-based dose of ribavirin and the recommended duration of treatment for genotypes 1 and 4 is 48 weeks [2, 3]. Furthermore, the cost of the new treatment is estimated to be 60,000–100,000 USD and therefore PEG-INF-α may still have a role especially in those patients living in developing countries and for whom access to the new drugs is not definite [4–8].

IFN-α alters the immune response in patients with CHC from T helper- (Th-) 2 to a Th1 mediated pattern to favour the eradication of the virus [9–12] and this is achieved through the modulation of several cytokines, including IFN-γ, interleukin (IL)-2, IL-6 and IL-10, tumour necrosis factor- (TNF-) α, and transforming growth factor-β (TGF-β) [13–16].

Activins, which are members of the TGF-β family, are homodimers of inhibin β-subunits (βA and βB), and the different dimerization of subunits gives rise to three proteins: activin-A (βA-βA), activin-B (βB-βB), and activin-AB (βA-βB), and their biological actions are tightly regulated by their binding protein, follistatin [17]. Activin-A and follistatin are expressed by the hepatocyte and they are involved in the regulation of liver regeneration. The expression of these proteins is altered in a variety of liver pathologies, including
viral hepatitis, liver fibrosis/cirrhosis, and hepatocellular carcinoma [18–22].

Activin-A and follistatin also play an important immunoregulatory role in the pathogenesis of inflammatory and fibrotic human diseases [23]. In this concept, activin-A can act as a pro- or anti-inflammatory agent depending on type of the disease and the cellular and immune contexts and its actions are blocked by follistatin [24, 25]. Moreover, activin-A may be a key regulator of humoral immune response and its secretion is up-regulated in activated Th2 clones [26–28].

Little is known about the effect of PEG-INF-α based therapy for the treatment of CHC on serum concentrations of activins and follistatin. Therefore, concentrations of activin-A, activin-B, and follistatin in serum samples collected at different times during the treatment protocol for genotypes 1 and 4 were compared with those obtained from healthy and treatment naïve patients with CHC genotypes 1 and 4. We also investigated whether serum concentrations of the candidate molecules differ between treatment responder and nonresponder and correlation studies were performed between the candidate molecules, viral load, and liver function parameters.

2. Patients and Methods

2.1. Ethical Approval. The study was approved by the Institutional Review Board and Ethics Committee of King Abdullah Medical City (IRB 12-028). All samples were collected following obtaining informed written consent from all the participants.

2.2. Study Design. The trial was a cross-sectional and serum samples were collected from 40 healthy blood donors and they served as negative control (NC) group. The NC group consisted of 20 males and 20 females (age range: 30–60 years). The participants did not report any current acute or chronic medical condition, history of hospitalisation, and no medication for significant clinical disease. Additionally, laboratory results for their haematological, biochemical, and metabolic parameters were within normal range.

Serum samples were also collected according to the inclusion and exclusion criteria (Table 1) from 6 different groups of patients with a total number of 125 patients diagnosed with CHC and for whom polymerase chain reaction following reverse transcription was positive for HCV RNA. The 6 groups were defined according to the time of their sample collection: positive control (PC) group included 33 infected patients who did not start their treatment protocol. The 4 weeks (4 W) group included 19 patients at week 4 after the initiation of 48 weeks of treatment protocol with pegylated-interferon-α based therapy who achieved a rapid viral response. The 12 weeks (12 W) group consisted of 22 patients at week 12 after the start of the treatment protocol. The 24 weeks (24 W) group consisted of 19 patients at week 24 following the initiation of treatment. The responder (R) group included samples collected at week 48 from 21 patients who achieved end of treatment viral response and who remained negative after 6 months from the termination of the treatment protocol. The non-responder (NR) group included samples collected from another 11 patients who were positive for HCV by PCR at the end of a 48-week treatment protocol.

All treated patients received PEG-INF-α-2a (Pegasys, Roche, Basel, Switzerland) at a dosage of 180 µg per week in combination with daily dose of ribavirin (Copegus, Roche) based on the body weight (1000 mg if <75 kg or 1200 mg if ≥75 kg).

The results of liver function parameters and viral load at the time of sample collection were performed as part of the routine laboratory follow-up.

2.3. Calculation of AST/Platelet Ratio Index (APRI). APRI was calculated using the following equation: (AST/upper limit of normal)/platelet count (x10⁹/L) × 100. The interpretation of the APRI results was performed according to previously published studies [29, 30]. Briefly, index ≤0.5 indicated normal liver with no or minimal fibrosis, >0.5 and ≤1.5 Progressive fibrotic stages (e.g. Metavir F1-to-F4) and >1.5 indicated liver cirrhosis. Only samples with ≤1.2 APRI were included into the study to avoid collecting samples from patients with liver cirrhosis.

2.4. Enzyme Linked Immunosorbent Assay (ELISA). ELISA was used for quantitative measurement of human activin-A (R&D systems, Minneapolis, USA), activin-B (Uscn Life Science Inc., Hubei, China), and follistatin (R&D systems, Minneapolis, USA). All samples were processed in duplicate and according to the manufacturer’s instructions. The optical density of the plates was measured within 10 min using a plate reader at 450 nm and correction at 560 nm as recommended by the manufacturer.

As reported by the manufacturer, the lowest detection limit of activin-A by the used kit is 3.7 pg/mL and the upper limit is 1500 pg/mL. The intra-assay and interassay precisions of the kit are 4.3% and 5.8%, respectively. The kit cross reacts by 0.2% and 0.45% with inhibin-A and activin-AB, respectively. The detection range of the activin-B kit is 15.6–1000 pg/mL and the minimum detectable dose is 6.4 pg/mL. The intra-assay and interassay precisions are <10% and <12%, respectively. Cross-reactions with the other activin/inhibin isoforms were not detected by the manufacturer.

2.5. Activin(s)/Follistatin Ratio Index. Activin-A/follistatin ratio index (AFRI), activin-B/follistatin ratio index (BFRI), and activins/follistatin ratio index (ASFRI) were calculated as follows, respectively: [activin-A/follistatin × 100], [activin-B/follistatin × 100], and [(activin-A + activin-B)/follistatin × 100].

2.6. Statistical Analysis. Statistical analysis of the results was performed using SPSS version 16. Cross-tabulation followed by Chi square (χ²) test was used for frequency analysis. According to data normality, either Student’s t-test or Mann-Whitney U test was used to compare between 2 groups. Furthermore, one-way ANOVA followed by LSD post hoc test or Kruskal-Wallis followed by Dunn’s post hoc test was used to compare between more than 2 groups depending on
the data homogeneity. Correlations were determined using Pearson's test. $P$ value < 0.05 was considered significant.

3. Results

3.1. Demographic Data and Routine Laboratory Parameters. There was no significant difference in the mean age, distribution of gender, viral genotype, viral load at diagnosis, and ALP either between the 7 study groups or within each group according to gender and viral genotype (Table 2). However, serum albumin, AST, ALT, and APRI were significantly different between the study groups (Table 2).

3.2. Activins and Follistatin in the Different Study Groups. Overall, activin-A, activin-B, follistatin, AFRI, BFRI, and ASFRI showed significant variation between the 7 study groups. CHC with no treatment (PC group) significantly increased serum concentrations of activin-A ($P = 0.01 \times 10^{-6}$), activin-B ($P = 0.003$), AFRI ($0.01 \times 10^{-6}$), BFRI ($P = 0.02$), ASFRI ($P = 0.0004$), and significantly decreased follistatin ($P = 0.03 \times 10^{-5}$) compared to the NC group (Figure 1).

Following the initiation of treatment, a significant decrease ($P < 0.05$) in the concentrations of activin-A, AFRI, BFRI, and ASFRI was observed at 4 W, 12 W, and 24 W compared to the PC group and the levels were similar to the NC ($P > 0.05$). Significant increase in the concentrations of follistatin ($P < 0.05$) was observed at 12 W and 24 W compared to the PC group and the levels were not different from the NC group (Figure 1). There was no significant change for activin-B following the initiation of treatment when compared to the PC group ($P > 0.05$) (Figure 1). Furthermore, there was no significant change between the 4 W, 12 W, and 24 W in serum levels of activin-A, activin-B, AFRI, BFRI, and ASFRI.

The responder group had serum concentrations of activin-A, AFRI, BFRI, ASFRI, and follistatin at similar levels seen in the NC, 4 W, 12 W, and 24 W groups ($P > 0.05$). However, activin-A ($P = 0.01 \times 10^{-4}$), AFRI ($P = 0.001$), BFRI ($P = 0.02$), and ASFRI ($0.03 \times 10^{-4}$) were significantly decreased and follistatin significantly increased ($P = 0.01 \times 10^{-5}$) compared to the PC group. There was no significant in activin-B levels when compared to the other groups.

In the nonresponder group, serum activin-A, activin-B, and follistatin were significantly different from all groups except for the PC group, where no significant difference was detected. However, significant differences were detected for AFRI, BFRI, and ASFRI when compared to all groups (Figure 1).

Activin-A and follistatin were significantly higher in male (331.1 ± 65.5 pg/mL and 1111.3 ± 267.8 pg/mL, resp.) compared to female (256.8 ± 70.1 pg/mL and 734.7 ± 185.9 pg/mL, resp.) participants in the control group ($P < 0.05$). However, there was no significant difference ($P > 0.05$) between both genders within each CHC group (data not shown).

3.3. Correlation of Serum Activins and Follistatin with Liver Enzymes, Albumin, and Viral Load. Activin-A significantly correlated positively with the viral load ($r = 0.716, P = 0.01 \times 10^{-7}$), AST ($r = 0.374, P = 0.0003$), and APRI ($r = 0.528, P = 0.01 \times 10^{-5}$) and negatively with albumin ($r = -0.570, P = 0.04 \times 10^{-5}$) (Table 3). Significant positive correlation was also observed between the viral load and AFRI ($r = 0.604, P = 0.01 \times 10^{-4}$) and ASFRI ($r = 0.534, P = 0.03 \times 10^{-3}$) (Figure 2).

4. Discussion

This current study is the first to report the effect of PEG-INF-α based therapy on serum concentrations of activin-A, activin-B, AFRI, BFRI, ASFRI, and follistatin in patients diagnosed with CHC. This is also the first report to show significant difference in serum concentrations of those proteins between treatment responders and nonresponders in patients infected with HCV genotypes 1 and 4 following PEG-INF-α based therapy for 48 weeks. Finally, our results showed a significant correlation for serum activin-A with the viral load and liver function parameters.
|                          | NC (n = 40) | PC (n = 33) | 4 W (n = 19) | 12 W (n = 22) | 24 W (n = 19) | R (n = 21) | NR (n = 11) |
|--------------------------|-------------|-------------|--------------|---------------|---------------|------------|-------------|
| Age (years)              | 39 ± 7.4    | 49.8 ± 16.3 | 41.5 ± 13.4  | 42 ± 11.5     | 44.9 ± 12.5   | 46 ± 13.4  | 42.1 ± 18.1 |
| Gender                   |             |             |              |               |               |            |             |
| Male                     | 20 (50%)    | 16 (48.4%)  | 11 (57.9%)   | 15 (68.1%)    | 13 (68.4%)    | 12 (57.1%) | 5 (45.5%)   |
| Female                   | 20 (50%)    | 17 (51.6%)  | 8 (42.1%)    | 7 (31.9%)     | 6 (31.6%)     | 9 (42.9%)  | 6 (55.5%)   |
| Genotype                 |             |             |              |               |               |            |             |
| GI                       | ND          | 14 (42.4%)  | 10 (52.9%)   | 10 (47.3%)    | 10 (55.5%)    | 11 (52.3%) | 3 (27.3%)   |
| G4                       | ND          | 19 (57.6%)  | 9 (41.1%)    | 12 (52.7%)    | 9 (45.5%)     | 10 (47.7%) | 8 (72.7%)   |
| Viral load at diagnosis (IU/mL) | ND | 1256194 ± 555544 | 1397057 ± 481355 | 1089313 ± 617246 | 999187 ± 400348 | 1048288 ± 303944 | 1165716 ± 457946 |
| Albumin (g/dL)           | 4.4 ± 0.2   | 3.66 ± 0.46a | 3.88 ± 0.43a | 3.84 ± 0.53a  | 4.03 ± 0.23a  | 3.91 ± 0.39a | 3.95 ± 0.48a |
| ALP (IU/L)               | 79.4 ± 21.6 | 120.2 ± 51.8 | 112.4 ± 35.8 | 100.6 ± 39.3  | 85.8 ± 26.5   | 87.8 ± 32.6 | 110.09 ± 42.8 |
| ALT (IU/L)               | 28 ± 11.2   | 63 ± 25.7a   | 53.3 ± 24.7a | 56.3 ± 26.2a  | 45 ± 14.3b    | 37.6 ± 20.8b | 38.9 ± 18.7b |
| AST (IU/L)               | 21 ± 7.6    | 43.4 ± 17.2a | 39.3 ± 16.2  | 38.3 ± 12.6   | 31.2 ± 8.3hc  | 28 ± 10.2hc  | 42.4 ± 20.4fc |
| APRI                     | 0.37 ± 0.07 | 0.85 ± 0.29a | 0.55 ± 0.23a | 0.77 ± 0.28a  | 0.66 ± 0.22ab | 0.65 ± 0.21ab | 0.72 ± 0.3a  |

ND = not done, a P < 0.05 compared to NC, b P < 0.05 compared to PC, c P < 0.05 compared to 4 W, d P < 0.05 compared to 12 W, e P < 0.05 compared to 24 W, and f P < 0.05 compared to R.
Figure 1: Mean ± SD of serum (a) activin-A, (b) activin-B, (c) follistatin, (d) AFRI, (e) BFRI, and (f) ASFRI in the different study groups (*p = 0.05 compared to NC, b p < 0.05 compared to PC, c p < 0.05 compared to 4W, d p < 0.05 compared to 12W, e p < 0.05 compared to 24W, and f p < 0.05 compared to R).
Figure 2: Correlation of serum activin-A with (a) viral load, (b) serum albumin, (c) AST, (d) APRI, (e) ALT, and (f) ALP by Pearson’s correlation test.
Table 3: Results of correlation analysis using Pearson’s test for activin-A, activin-B, follistatin, AFRI, BFRI, and ASFRI with viral load, albumin, liver enzymes, and APRI.

|                      | Viral load at sample collection | Albumin | ALP | ALT | AST | APRI |
|----------------------|--------------------------------|---------|-----|-----|-----|------|
| Activin-A            |                                |         |     |     |     |      |
| R value              | 0.716*                         | −0.570* | 0.270* | 0.186 | 0.374* | 0.528* |
| P value              | 0.000000001                     |         | 0.002 | 0.36 | 0.0003 | 0.000001 |
| Activin-B            |                                |         |     |     |     |      |
| R value              | 0.113                          | 0.107   | 0.063 | −0.146 | −0.023 | 0.157 |
| P value              | 0.21                           |         | 0.48  | 0.1  | 0.8  | 0.076 |
| Follistatin          |                                |         |     |     |     |      |
| R value              | −0.244                         | −0.065  | 0.084 | −0.072 | −0.061 | 0.051 |
| P value              | 0.007                          |         | 0.35  | 0.42 | 0.49 | 0.56 |
| AFRI                 |                                |         |     |     |     |      |
| R value              | 0.604*                         | −0.289  | 0.098 | 0.067 | 0.146 | 0.233 |
| P value              | 0.000001                       |         | 0.27  | 0.45 | 0.1  | 0.008 |
| BFRI                 |                                |         |     |     |     |      |
| R value              | 0.222                          | 0.02    | −0.052 | −0.068 | −0.077 | −0.069 |
| P value              | 0.01                           |         | 0.56  | 0.44 | 0.39 | 0.44 |
| ASFRI                |                                |         |     |     |     |      |
| R value              | 0.534*                         | −0.219  | 0.056 | 0.034 | 0.100 | 0.158 |
| P value              | 0.00003                        |         | 0.53  | 0.42 | 0.26 | 0.07 |

*p < 0.01.

Our results suggest that HCV and/or its associated liver fibrosis modulated serum activin-A and follistatin. Additionally, both molecules, but not activin-B, could be modulated through PEG-INF-α based therapy in CHC patients.

The expressions of activin subunits and follistatin have been reported in the liver and alteration in their expression has been linked with several liver diseases [18]. Serum activin-A significantly increases in liver fibrosis and cirrhosis induced by viral and non-viral factors [31]. Serum activin-A was linked to viral replication in chronic hepatitis B and hepatitis C [19], and it correlated significantly with liver damage associated with HCV [20]. Hence, it has been suggested that pathological alteration in the hepatic expression of activin and follistatin could lead to impaired liver regeneration [32] and the development of liver fibrosis, cirrhosis, and hepatocellular carcinoma [33]. Our results correlate and support the previous findings as there was a significant decrease in serum follistatin and significant increase in serum activin-A, activin-B, AFRI, BFRI, and ASFRI in patients with CHC and who did not receive treatment compared to healthy controls.

APRI has been proposed as a predictor of liver fibrosis and cirrhosis in CHC to replace liver biopsy in a substantial proportion of patients [34]. Several studies have confirmed the high sensitivity and specificity and significant correlation of APRI with both the stage of liver fibrosis and the grade of activity [29]. The present study showed significant positive correlations of serum activin-A with liver enzymes and APRI and a significant negative correlation with serum albumin, suggesting that the observed increase in activin-A and decrease in follistatin in the “PC” and “nonresponder” groups could be due to the CHC associated liver fibrosis. Therefore, we hypothesize that serum activin-A could be a promising serum marker for the diagnosis of liver fibrosis/cirrhosis associated with CHC. However, further studies are required to support our suggestion.

The current results also showed significant positive correlations for activin-A, AFRI and ASFRI with the viral load, proposing that serum activin-A and follistatin could be modulated by HCV through either the associated liver damage or as part of the host immune response to control the viral infection. Activin-A and follistatin are elements of both innate and humoral immune responses [24, 25] and both proteins have been described in immune response to several pathogens including viruses [35]. Activin-A and follistatin are also important regulators of regulatory T-cells [36], natural killer cells [37], and dendritic cells [38], which are known to play an important role in controlling CHC infection [10]. Furthermore, activin-A has been shown to promote the production of Th2 cytokines, which promote the development of humoral response and the subsequent development of liver fibrosis [9, 10]. Hence, we suggest that the observed changes in in serum activin-A/follistatin could represent the response by the host to the viral damage which triggers an inflammatory response driven by activin-A. However, additional studies are needed to explore whether activin-A and/or follistatin are involved in the immune response to HCV.

PEG-INF-α based therapy is a key component of CHC treatment through the induction of a Th1 immune response [39]. INF-α promotes Th1 response through the increase in
the production of several cytokines by the hepatocyte and immune cells [16]. Additionally, IFN-α alters the production of immunoglobulin, decreases T regulatory cell function [40], and stimulates the production of toll like receptors (TLR) [39].

Gathered data from published reports suggest that activin-A/follistatin might be a target for PEG-INF-α based therapy for the eradication of CHC. The expressions of TLR-2 and 4 increase significantly following PEG-INF-α based therapy in patients with CHC [41] and they are potent regulators of the release of activin-A [42]. In addition, PEG-INF-α increases the production of TNF-α [43] and decreases serum IL-6 and IL-10 in patients with CHC [14]. These cytokines have also been reported to be regulated by activin-A [36]. Moreover, activin-A has been reported to modulate the release of INF-γ [44], which plays an important role in controlling CHC following PEG-INF-α based therapy [45]. Consequently, the observed significant alteration in activin-A and follistatin after 4, 12, and 24 weeks of treatment could be mediated by the therapy used. More studies are required to illustrate the kinetics and source of serum activin-A and follistatin during the course of PEG-INF-α based therapy.

A limitation for our study is that we adopted a cross-sectional design and performing a longitudinal prospective cohort study would reveal the true kinetics of serum activin-A and follistatin following PEG-INF-α based therapy and their correlation with the viral load during the course of treatment. Subsequently, it would allow a better understanding of the effect(s) of the currently used treatment for CHC and viral load on serum activins and follistatin. However, the current study is a preliminary report and we are currently processing future studies with longitudinal design to measure the clinical value of activins and follistatin in the prediction of treatment outcome in CHC.

In conclusion, serum concentrations of activin-A and follistatin are different between patients with and without HCV and at the different stages of IFN therapy. Activin-A and follistatin appear to be influenced by PEG-INF-α based therapy and they seem to correlate with liver damage associated with CHC. Further studies are needed to illustrate the role(s) of activin-follistatin axis in CHC and to explore the effect(s) of PEG-INF-α therapy on the expression of activins and follistatin by the hepatocyte.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

The authors thank KACST for the financial support of the study (12-MED2302-10) under the National Science, Technology and Innovation Plan. The study was funded by a Grant (12-MED2302-10) under the National Science, Technology and Innovation Plan from King Abdul Aziz City for Sciences and Technology (KACST), Riyadh, KSA.

References

[1] F. M. Averhoff, N. Glass, and D. Holtzman, “Global burden of hepatitis C: considerations for healthcare providers in the United States,” Clinical Infectious Diseases, vol. 55, supplement 1, pp. 10–15, 2012.

[2] M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C: an update,” Hepatology, vol. 49, no. 4, pp. 1335–1374, 2009.

[3] C. Lee, “Daclatasvir: potential role in hepatitis C,” Drug Design, Development and Therapy, vol. 7, pp. 1223–1233, 2013.

[4] C. M. Lange and S. Zeuzem, “Perspectives and challenges of interferon-free therapy for chronic hepatitis C,” Journal of Hepatology, vol. 58, pp. 583–592, 2013.

[5] Z. M. Younossi, M. E. Singer, H. M. Mir, L. Henry, and S. Hunt, “Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients,” Journal of Hepatology, vol. 60, no. 3, pp. 530–537, 2014.

[6] K. Chan, M. N. Lai, E. J. Grossell et al., “Cost effectiveness of direct-acting antiviral therapy for treatment-naïve patients with chronic HCV genotype 1 infection in the veterans health administration,” Clinical Gastroenterology and Hepatology, vol. 11, no. 11, pp. 1503–1510, 2013.

[7] S. A. Ferrante, J. Chhawal, C. A. Brass, A. C. El Khoury, F. Poordad, J. P. Bronowicki et al., “Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study,” BMC Infectious Diseases, vol. 13, article 190, 2013.

[8] S. Cure, F. Bianic, S. Gavart, S. Curtis, S. Lee, and G. Dusheiko, “Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients,” Journal of Medical Economics, vol. 17, no. 1, pp. 65–76, 2014.

[9] M. Moser and K. M. Murphy, “Dendritic cell regulation of TH1-TH2 development,” Nature Immunology, vol. 1, no. 3, pp. 199–205, 2000.

[10] P. Fallahi, C. Ferri, S. M. Ferrari, A. Corrado, D. Sansonno, and A. Antonelli, “Cytokines and HCV-related disorders,” Clinical and Developmental Immunology, vol. 2012, Article ID 468107, 10 pages, 2012.

[11] J. D. Farrar and K. M. Murphy, “Type I interferons and T helper development,” Immunology Today, vol. 21, no. 10, pp. 484–489, 2000.

[12] M. A. Jimenez-Sousa, R. Almansa, C. de la Fuente et al., “Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin,” European Cytokine Network, vol. 21, no. 2, pp. 84–91, 2010.

[13] E. P. M. Corssmit, J. de Metz, H. P. Sauerwein, and J. A. Romijn, “Biologic responses to IFN-α administration in humans,” Journal of Interferon and Cytokine Research, vol. 20, no. 12, pp. 1039–1047, 2000.

[14] M. Ueyama, M. Nakagawa, N. Sakamoto et al., “Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin,” Antiviral Therapy, vol. 16, no. 7, pp. 1081–1091, 2011.

[15] E. J. Pavon-Castillero, P. Munoz-de-Rueda, R. Lopez-Segura et al., “Importance of IL-10 and IL-6 during chronic hepatitis C genotype 1 treatment and their relation with IL28B,” Cytokine, vol. 61, no. 2, pp. 595–601, 2013.
M.Y. Elsamak, G.M. Amin, G.M. Khalil, W.S. Ragab, and M. K. Ogawa, M. Funaba, Y. Chen, and M. Tsujimoto, “Activin A and follistatin in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis,” Clinical Biochemistry, vol. 39, no. 6, pp. 623–629, 2006.

M. Grusch, C. Drucker, B. Peter-Vörosmarty et al., “Deregulation of the activin/follistatin system in hepatocarcinogenesis,” Journal of Hepatology, vol. 45, no. 5, pp. 673–680, 2006.

M. K. Jain, B. Adams-Huet, D. Terekhova et al., interferon-α and γ. Chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients,” Journal of Viral Hepatitis, 2014.

S. Werner and C. Alzheimer, “Roles of activin in tissue repair, fibrosis, and inflammatory disease,” Cytokine and Growth Factor Reviews, vol. 17, no. 3, pp. 157–171, 2006.

K. L. Jones, A. Mansell, S. Patella et al., “Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 1, pp. 16239–16244, 2007.

D. J. Phillips, D. M. de Kretser, and M. P. Hedger, “Activin and related proteins in inflammation: not just interested bystanders,” Cytokine and Growth Factor Reviews, vol. 20, no. 2, pp. 153–164, 2009.

K. Ogawa, M. Funaba, Y. Chen, and M. Tsujimoto, “Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages,” Journal of Immunology, vol. 177, no. 10, pp. 6787–6794, 2006.

K. Ogawa, M. Funaba, and M. Tsujimoto, “A dual role of activin A in regulating immunoglobulin production of B cells,” Journal of Leukocyte Biology, vol. 83, no. 6, pp. 1451–1458, 2008.

D. J. Phillips, K. L. Jones, J.-P. Y. Scheerlinck, M. P. Hedger, and D. M. de Kretser, “Evidence for activin A and follistatin involvement in the systemic inflammatory response,” Molecular and Cellular Endocrinology, vol. 180, no. 1-2, pp. 155–162, 2001.

S. A. Fouad, S. Esmit, D. Omran, L. Rashid, and M. H. Kobaisi, “Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection,” World Journal of Gastroenterology, vol. 18, no. 23, pp. 2988–2994, 2012.

F. Guzelbulut, M. Sezikli, Z. Akkan-Cetinkaya, B. Yasar, S. Ozkara, and A. O. Kudras-Ovunc, “AST-platelet ratio index in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis B,” The Turkish Journal of Gastroenterology, vol. 23, pp. 353–358, 2012.

A. Voumversionakis, G. Notas, M. Koullentaki, M. Georgiadou, S. Kizonomos, and E. Kouroumalis, “Increased serum activin-A differentiates alcoholic cirrhosis from other aetiologies,” European Journal of Clinical Investigation, vol. 42, no. 8, pp. 815–822, 2012.

R. D. Hughes and L. W. Evans, “Activin A and follistatin in acute liver failure,” European Journal of Gastroenterology and Hepatology, vol. 15, no. 2, pp. 127–131, 2003.

E. Kreidl, D. Ozturk, T. Metzner, W. Berger, and M. Grusch, “Activins and follistatins: emerging roles in liver physiology and cancer,” World Journal of Hepatology, vol. 1, no. 1, pp. 17–27, 2009.

C.-T. Wai, J. K. Greenson, R. J. Fontana et al., “A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C,” Hepatology, vol. 38, no. 2, pp. 518–526, 2003.

Y. Nishino, R. Ooishi, S. Kurokawa et al., “Gene expression of the TGF-β family in rat brain infected with Borna disease virus,” Microbes and Infection, vol. 11, no. 8-9, pp. 737–743, 2009.

M. Semitekolou, T. Alissafi, M. Aggelakopoulou et al., “Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway disease,” Journal of Experimental Medicine, vol. 206, no. 8, pp. 1769–1785, 2009.

N. C. Robson, H. Wei, T. McAlpine, N. Kirkpatrick, J. Cebon, and E. Maraskovsky, “Activin-A attenuates several human natural killer cell functions,” Blood, vol. 113, no. 14, pp. 3218–3225, 2009.

S. Scutera, E. Riboldi, R. Daniele et al., “Production and function of activin A in human dendritic cells,” European Cytokine Network, vol. 19, no. 1, pp. 60–68, 2008.

M. H. Heim, “Interferons and hepatitis C virus,” Swiss Medical Weekly, vol. 142, Article ID w13586, 2012.

I. Krause, G. Valesini, R. Scivo, and Y. Shoenfeld, “Autoimmune aspects of cytokine and anticytokine therapies,” American Journal of Medicine, vol. 115, no. 5, pp. 390–397, 2003.

T. Hammond, S. Lee, M. W. Watson et al., “Toll-like receptor (TLR) expression on CD4+ and CD8+ T-cells in patients chronically infected with hepatitis C virus,” Cellular Immunology, vol. 264, no. 2, pp. 150–155, 2010.

K. L. Jones, D. M. de Kretser, I. J. Clarke, J.-P. Y. Scheerlinck, and D. J. Phillips, “Characterisation of the rapid release of activin A following acute lipopolysaccharide challenge in the ewe,” Journal of Endocrinology, vol. 182, no. 1, pp. 69–80, 2004.

G. Ahlenstiel, B. Edlich, L. J. Hogdal et al., “Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C,” Gastroenterology, vol. 141, no. 4, pp. 1231–e2, 2011.

K. S. Famulski, B. Eis, L. Billesberger, and P. F. Halloran, “Interferon-γ and donor MHC class I control alternative macrophage activation and activin expression in rejecting kidney allografts: a shift in the Th1-Th2 paradigm,” American Journal of Transplantation, vol. 8, no. 3, pp. 547–556, 2008.

T. N. Pham, D. M. Lin, P. M. Mulrooney-Cousins et al., “Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment,” Journal of Medical Virology, vol. 85, no. 3, pp. 441–448, 2013.